| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
WEE1 kinase
|
|---|---|
| ln Vitro |
ZINC-95803150 is a novel and potent WEE1 kinase inhibitor. WEE1 is a serine/threonine kinase that phosphorylates and inactivates CDK1/cyclin B complexes, thereby regulating the G2/M checkpoint. Inhibition of WEE1 abrogates this checkpoint, forcing cells with DNA damage to enter mitosis prematurely, leading to mitotic catastrophe and cell death. The compound's activity in inhibiting WEE1 makes it a potential therapeutic agent for cancers with defective DNA repair pathways.
|
| ln Vivo |
In vitro studies demonstrate that ZINC-95803150 inhibits WEE1 kinase activity, leading to abrogation of the G2/M cell cycle checkpoint. Cells treated with the compound show increased sensitivity to DNA-damaging agents due to premature mitotic entry. The compound's potency and selectivity for WEE1 over other kinases contribute to its utility as a research tool for studying cell cycle regulation.
|
| Enzyme Assay |
WEE1 kinase activity is measured using radiometric or fluorescence-based kinase assays with recombinant WEE1 enzyme and appropriate substrates. IC50 values are determined from dose-response curves to establish the compound's potency. Selectivity profiling is conducted against a panel of kinases to confirm specificity for WEE1.
|
| Cell Assay |
Cellular potency is evaluated in cancer cell lines by measuring WEE1 inhibition and its effects on cell cycle progression. Cells are treated with ZINC-95803150 at various concentrations, and CDK1 phosphorylation is measured by Western blot. Cell cycle analysis is performed using flow cytometry to assess G2/M checkpoint abrogation. Cell viability and apoptosis are measured to evaluate the compound's antiproliferative effects.
|
| Animal Protocol |
In vivo efficacy studies are conducted in mouse xenograft models of cancer. ZINC-95803150 is administered via appropriate routes at various doses. Tumor growth inhibition is measured over time, and pharmacodynamic biomarkers including CDK1 phosphorylation are assessed in tumor tissues. The compound's ability to sensitize tumors to DNA-damaging agents is evaluated in combination studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for ZINC-95803150 are limited as the compound is primarily used as a research tool. The compound is soluble in DMSO for formulation. In vivo formulations may be prepared using DMSO:Tween 80:Saline = 10:5:85 for injection. The compound has a LogP of 1.17, indicating moderate lipophilicity. Detailed PK parameters are available from preclinical studies.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for ZINC-95803150 are limited as the compound is primarily used for research purposes. Standard laboratory safety precautions should be observed during handling. The compound is not intended for human therapeutic use and has not been evaluated in formal toxicology studies.
|
| Additional Infomation |
ZINC-95803150 is a WEE1 kinase inhibitor being developed as a research tool for studying cell cycle regulation and DNA damage response. WEE1 inhibition is a promising therapeutic strategy in oncology, particularly for tumors with p53 mutations that rely on the G2/M checkpoint for survival. The compound's molecular formula is C12H16N2 with a molecular weight of 188.27. ZINC-95803150 remains a research tool for studying WEE1 biology and cell cycle regulation.
|
| Molecular Formula |
C12H16N2
|
|---|---|
| Molecular Weight |
188.274
|
| Exact Mass |
188.131
|
| Elemental Analysis |
C, 76.55; H, 8.57; N, 14.88
|
| CAS # |
1092794-11-0
|
| Related CAS # |
1092795-12-4 (2HCl);1092794-11-0;
|
| PubChem CID |
44595898
|
| Appearance |
Solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
328.0±42.0 °C at 760 mmHg
|
| Flash Point |
133.2±23.0 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.639
|
| LogP |
1.17
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
14
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(C)CC2C=C(C=CC=2C2(C1)CC2)N
|
| InChi Key |
GXUFVBWYQHTXDP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H16N2/c1-14-7-9-6-10(13)2-3-11(9)12(8-14)4-5-12/h2-3,6H,4-5,7-8,13H2,1H3
|
| Chemical Name |
2'-Methyl-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-amine
|
| Synonyms |
ZINC-95803150ZINC95803150 ZINC 95803150
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3115 mL | 26.5576 mL | 53.1152 mL | |
| 5 mM | 1.0623 mL | 5.3115 mL | 10.6230 mL | |
| 10 mM | 0.5312 mL | 2.6558 mL | 5.3115 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
